All In Biotech

Drug Trial Radar · NCT05316922

TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients

Protection From Iatrogenic Hypothyroidism Patients With MBL and Pediatric Patients With HL and Non-HL Needing Radiotherapy on Thyroid Site

Last checked: Nov 20, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Dec 13, 2021

Primary completion

Sep 30, 2029

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To offer the possibility of a treatment that could achieve a meaningful reduction in the incidence of post-radiation therapy hypothyroidism. Thyroid dysfunction may develop from a few months to several years after patients have completed their radiation treatment. In children with chronic diseases, or given lengthy anti-neoplastic treatments, recurrent or persistent endocrine disorders may have a negative effect on growth and development into adulthood.

Conditions

  • Hypothyroidism; Irradiation

Interventions

  • LevothyroxineDrug

    Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hypothyroidism-free survivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.